CY2019025I1 - Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης - Google Patents

Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης

Info

Publication number: CY2019025I1
Authority: CY; Cyprus
Prior art keywords: pharmaceutical composition; reverse transcription; nucleoside reverse; transcription inhibitor; inhibitor
Prior art date: 2010-03-30

Application number

CY2019025C

Other languages

English (en)

Other versions

CY2019025I2 (el

Original Assignee

Merck Canada Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-30

Filing date

2019-05-16

Publication date

2019-11-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2019025(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-05-16 Application filed by Merck Canada Inc. filed Critical Merck Canada Inc.

2019-11-27 Publication of CY2019025I1 publication Critical patent/CY2019025I1/el

2019-11-27 Publication of CY2019025I2 publication Critical patent/CY2019025I2/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CY2019025C 2010-03-30 2019-05-16 Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης CY2019025I2 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US31882410P	2010-03-30	2010-03-30
US32157310P	2010-04-07	2010-04-07
EP11761856.1A EP2552902B1 (en)	2010-03-30	2011-03-28	Non-nucleoside reverse transcriptase inhibitors

Publications (2)

Publication Number	Publication Date
CY2019025I1 true CY2019025I1 (el)	2019-11-27
CY2019025I2 CY2019025I2 (el)	2019-11-27

Family

ID=44710363

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CY20171100114T CY1118774T1 (el)	2010-03-30	2017-01-25	Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
CY2019026C CY2019026I2 (el)	2010-03-30	2019-05-16	Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης
CY2019025C CY2019025I2 (el)	2010-03-30	2019-05-16	Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CY20171100114T CY1118774T1 (el)	2010-03-30	2017-01-25	Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
CY2019026C CY2019026I2 (el)	2010-03-30	2019-05-16	Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης

Country Status (44)

Country	Link
US (2)	US8486975B2 (el)
EP (2)	EP2552902B1 (el)
JP (2)	JP5281718B2 (el)
KR (1)	KR101421861B1 (el)
CN (1)	CN102971308B (el)
AR (1)	AR080859A1 (el)
AU (1)	AU2011235568B2 (el)
BR (1)	BR112012024691B1 (el)
CA (1)	CA2794377C (el)
CL (1)	CL2012002744A1 (el)
CO (1)	CO6630126A2 (el)
CR (1)	CR20120503A (el)
CY (3)	CY1118774T1 (el)
DK (2)	DK2552902T3 (el)
DO (1)	DOP2012000256A (el)
EA (1)	EA024804B1 (el)
EC (1)	ECSP12012201A (el)
ES (2)	ES2609636T3 (el)
FI (1)	FIC20190021I1 (el)
GE (1)	GEP20156368B (el)
HN (1)	HN2012002039A (el)
HR (2)	HRP20150427T1 (el)
HU (4)	HUE025336T2 (el)
IL (2)	IL222030A (el)
LT (3)	LT2924034T (el)
LU (2)	LUC00113I9 (el)
MA (1)	MA34170B1 (el)
ME (2)	ME02570B (el)
MX (1)	MX2012011379A (el)
MY (1)	MY163979A (el)
NI (1)	NI201200146A (el)
NL (1)	NL300980I2 (el)
NO (2)	NO2019019I1 (el)
NZ (1)	NZ602670A (el)
PE (1)	PE20130158A1 (el)
PH (1)	PH12012501923A1 (el)
PL (2)	PL2552902T3 (el)
PT (2)	PT2924034T (el)
RS (2)	RS54017B1 (el)
SG (1)	SG184347A1 (el)
SI (2)	SI2552902T1 (el)
TN (1)	TN2012000455A1 (el)
TW (1)	TWI458719B (el)
WO (1)	WO2011120133A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE025336T2 (en) *	2010-03-30	2016-03-29	Merck Canada Inc	Non-nucleoside reverse transcriptase inhibitors
EP2625292B1 (en)	2010-10-07	2018-12-05	The General Hospital Corporation	Biomarkers of cancer
US9150539B2 (en)	2012-09-26	2015-10-06	Merck Sharp & Dohme Corp.	Crystalline form of a reverse transcriptase inhibitor
JO3470B1 (ar) *	2012-10-08	2020-07-05	Merck Sharp & Dohme	مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
BR112015012843B8 (pt)	2012-12-05	2023-04-25	Merck Sharp & Dohme	Método para sintetizar o composto
CN105722392B (zh) *	2013-11-22	2019-07-23	默沙东公司	非核苷逆转录酶抑制剂的组合物
ES2977643T3 (es) *	2013-12-04	2024-08-28	Merck Sharp & Dohme Llc	Proceso para fabricar inhibidores de la transcriptasa inversa
LT3125894T (lt)	2014-04-01	2020-12-10	Merck Sharp & Dohme Corp.	Živ atvirkštinės transkriptazės inhibitorių provaistai
EP3760208B1 (en)	2014-06-25	2024-05-29	The General Hospital Corporation	Targeting human satellite ii (hsatii)
KR102774942B1 (ko)	2015-12-02	2025-02-27	머크 샤프 앤드 돔 엘엘씨	도라비린, 테노포비르 디소프록실 푸마레이트 및 라미부딘을 함유하는 제약 조성물
US11077050B2 (en)	2017-03-24	2021-08-03	Merck Sharp & Dohme Corp.	Formulation for parenteral administration
EP3612226A1 (en)	2017-04-18	2020-02-26	Cipla Limited	Combination therapy for use in treating retroviral infections
CN112533613A (zh)	2018-02-06	2021-03-19	通用医疗公司	作为肿瘤免疫应答的生物标志物的重复rna
US12005072B2 (en)	2018-07-17	2024-06-11	Merck Sharp & Dohme Llc	HIV drug combination for increasing barrier against resistance
AU2019402998B2 (en)	2018-12-18	2022-12-15	Merck Sharp & Dohme Llc	Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells
CN110801455B (zh) *	2019-11-12	2020-06-02	河北医科大学第二医院	用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) *	2021-12-27	2023-04-25	甘肃皓天医药科技有限责任公司	一种多拉韦林中间体的制备方法
CN114349690B (zh) *	2022-02-15	2023-04-25	甘肃皓天医药科技有限责任公司	一种多拉韦林中间体合成方法
CN116903590A (zh) *	2023-06-06	2023-10-20	延边大学	一种含杂环结构的吡啶酮类化合物及其制备方法和用途
CN120157613A (zh) *	2023-12-15	2025-06-17	山东诚创蓝海医药科技有限公司	多拉韦林中间体及其应用和合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9904045D0 (sv)	1999-11-09	1999-11-09	Astra Ab	Compounds
TW200423930A (en) *	2003-02-18	2004-11-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en)	2003-03-24	2005-02-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitorsⅠ
CA2518823A1 (en)	2003-03-24	2004-10-07	F.Hoffmann-La Roche Ag	Benzyl-pyridazinons as reverse transcriptase inhibitors
US7166738B2 (en)	2004-04-23	2007-01-23	Roche Palo Alto Llc	Non-nucleoside reverse transcriptase inhibitors
WO2005102989A1 (en)	2004-04-23	2005-11-03	F. Hoffmann-La Roche Ag	Non-nucleoside reverse transcriptase inhibitors
EP1831157A2 (en)	2004-12-22	2007-09-12	Pfizer Limited	Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es)	2005-07-22	2007-12-05	Merck & Co Inc	Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
ES2320042T3 (es)	2005-10-19	2009-05-18	F. Hoffmann-La Roche Ag	Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida.
KR20080056220A (ko)	2005-10-19	2008-06-20	에프. 호프만-라 로슈 아게	페닐-아세트아마이드 ｎｎｒｔ 저해제
TW200831085A (en)	2006-12-13	2008-08-01	Merck & Co Inc	Non-nucleoside reverse transcriptase inhibitors
WO2009067166A2 (en)	2007-11-20	2009-05-28	Merck & Co., Inc.	Non-nucleoside reverse transcriptase inhibitors
HUE025336T2 (en) *	2010-03-30	2016-03-29	Merck Canada Inc	Non-nucleoside reverse transcriptase inhibitors

2011
- 2011-03-28 HU HUE11761856A patent/HUE025336T2/en unknown
- 2011-03-28 MX MX2012011379A patent/MX2012011379A/es active IP Right Grant
- 2011-03-28 MA MA35324A patent/MA34170B1/fr unknown
- 2011-03-28 EA EA201290976A patent/EA024804B1/ru active Protection Beyond IP Right Term
- 2011-03-28 CN CN201180018074.2A patent/CN102971308B/zh active Active
- 2011-03-28 EP EP11761856.1A patent/EP2552902B1/en active Active
- 2011-03-28 PH PH1/2012/501923A patent/PH12012501923A1/en unknown
- 2011-03-28 HR HRP20150427TT patent/HRP20150427T1/hr unknown
- 2011-03-28 MY MYPI2012004342A patent/MY163979A/en unknown
- 2011-03-28 DK DK11761856.1T patent/DK2552902T3/en active
- 2011-03-28 HU HUE15157348A patent/HUE031785T2/en unknown
- 2011-03-28 PL PL11761856T patent/PL2552902T3/pl unknown
- 2011-03-28 BR BR112012024691-7A patent/BR112012024691B1/pt active IP Right Grant
- 2011-03-28 ES ES15157348.2T patent/ES2609636T3/es active Active
- 2011-03-28 CA CA2794377A patent/CA2794377C/en active Active
- 2011-03-28 PL PL15157348T patent/PL2924034T3/pl unknown
- 2011-03-28 NZ NZ602670A patent/NZ602670A/en unknown
- 2011-03-28 PT PT151573482T patent/PT2924034T/pt unknown
- 2011-03-28 RS RS20150340A patent/RS54017B1/sr unknown
- 2011-03-28 ME MEP-2016-282A patent/ME02570B/me unknown
- 2011-03-28 WO PCT/CA2011/000320 patent/WO2011120133A1/en not_active Ceased
- 2011-03-28 JP JP2012538161A patent/JP5281718B2/ja active Active
- 2011-03-28 LT LTEP15157348.2T patent/LT2924034T/lt unknown
- 2011-03-28 EP EP15157348.2A patent/EP2924034B1/en active Active
- 2011-03-28 DK DK15157348.2T patent/DK2924034T3/en active
- 2011-03-28 SG SG2012072401A patent/SG184347A1/en unknown
- 2011-03-28 RS RS20161093A patent/RS55505B1/sr unknown
- 2011-03-28 ES ES11761856.1T patent/ES2536295T3/es active Active
- 2011-03-28 US US13/073,631 patent/US8486975B2/en active Active
- 2011-03-28 PT PT117618561T patent/PT2552902E/pt unknown
- 2011-03-28 KR KR1020127025733A patent/KR101421861B1/ko active Active
- 2011-03-28 GE GEAP201112882A patent/GEP20156368B/en unknown
- 2011-03-28 PE PE2012001823A patent/PE20130158A1/es active IP Right Grant
- 2011-03-28 AU AU2011235568A patent/AU2011235568B2/en active Active
- 2011-03-28 SI SI201130491T patent/SI2552902T1/sl unknown
- 2011-03-28 SI SI201131054A patent/SI2924034T1/sl unknown
- 2011-03-28 ME MEP-2015-76A patent/ME02181B/me unknown
- 2011-03-29 AR ARP110101028A patent/AR080859A1/es active IP Right Grant
- 2011-03-29 TW TW100110833A patent/TWI458719B/zh active
2012
- 2012-09-20 IL IL222030A patent/IL222030A/en active Protection Beyond IP Right Term
- 2012-09-20 TN TNP2012000455A patent/TN2012000455A1/en unknown
- 2012-09-27 HN HN2012002039A patent/HN2012002039A/es unknown
- 2012-09-28 NI NI201200146A patent/NI201200146A/es unknown
- 2012-09-28 DO DO2012000256A patent/DOP2012000256A/es unknown
- 2012-09-28 CL CL2012002744A patent/CL2012002744A1/es unknown
- 2012-10-01 CO CO12171897A patent/CO6630126A2/es active IP Right Grant
- 2012-10-01 EC ECSP12012201 patent/ECSP12012201A/es unknown
- 2012-10-01 CR CR20120503A patent/CR20120503A/es unknown
2013
- 2013-05-23 JP JP2013108533A patent/JP5886790B2/ja not_active Expired - Fee Related
- 2013-07-03 US US13/934,633 patent/US20130296382A1/en not_active Abandoned
2014
- 2014-06-23 IL IL233334A patent/IL233334A/en active IP Right Grant
2016
- 2016-12-09 HR HRP20161680TT patent/HRP20161680T1/hr unknown
2017
- 2017-01-25 CY CY20171100114T patent/CY1118774T1/el unknown
2019
- 2019-04-09 HU HUS1900021C patent/HUS1900021I1/hu unknown
- 2019-04-09 HU HUS1900022C patent/HUS1900022I1/hu unknown
- 2019-04-11 LT LTPA2019507C patent/LTC2924034I2/lt unknown
- 2019-04-11 LT LTPA2019506 patent/LTC2552902I2/lt unknown
- 2019-04-16 NL NL300980C patent/NL300980I2/nl unknown
- 2019-04-17 LU LU00113C patent/LUC00113I9/fr unknown
- 2019-04-17 FI FIC20190021C patent/FIC20190021I1/fi unknown
- 2019-04-17 LU LU00114C patent/LUC00114I2/fr unknown
- 2019-04-24 NO NO2019019C patent/NO2019019I1/no unknown
- 2019-04-24 NO NO2019018C patent/NO2019018I1/no unknown
- 2019-05-16 CY CY2019026C patent/CY2019026I2/el unknown
- 2019-05-16 CY CY2019025C patent/CY2019025I2/el unknown

Also Published As

Publication number	Publication date
EP2924034B1 (en)	2016-11-02
PT2924034T (pt)	2017-01-06
ME02570B (me)	2017-06-20
RS54017B1 (sr)	2015-10-30
LTPA2019506I1 (lt)	2019-04-25
HN2012002039A (es)	2015-08-24
BR112012024691B1 (pt)	2020-11-17
GEP20156368B (en)	2015-09-25
CY1118774T1 (el)	2017-07-12
PT2552902E (pt)	2015-06-02
EP2924034A1 (en)	2015-09-30
LT2924034T (lt)	2016-12-27
CO6630126A2 (es)	2013-03-01
IL233334A0 (en)	2014-09-01
MY163979A (en)	2017-11-15
DK2924034T3 (en)	2017-02-06
DK2552902T3 (en)	2015-06-15
ECSP12012201A (es)	2012-10-30
SI2552902T1 (sl)	2015-10-30
CR20120503A (es)	2013-01-09
FIC20190021I1 (fi)	2019-04-17
HUE025336T2 (en)	2016-03-29
CA2794377A1 (en)	2011-10-06
NZ602670A (en)	2014-09-26
CY2019026I1 (el)	2020-05-29
EA024804B1 (ru)	2016-10-31
AU2011235568B2 (en)	2013-09-12
BR112012024691A2 (pt)	2019-07-02
WO2011120133A1 (en)	2011-10-06
MA34170B1 (fr)	2013-04-03
MX2012011379A (es)	2012-11-30
TWI458719B (zh)	2014-11-01
CL2012002744A1 (es)	2012-12-14
NO2019019I1 (no)	2019-04-24
TW201139409A (en)	2011-11-16
HRP20150427T1 (hr)	2015-07-03
NO2019018I1 (no)	2019-04-24
PL2552902T3 (pl)	2015-10-30
ES2536295T3 (es)	2015-05-22
TN2012000455A1 (en)	2014-01-30
US20130296382A1 (en)	2013-11-07
RS55505B1 (sr)	2017-05-31
HK1209121A1 (en)	2016-03-24
US8486975B2 (en)	2013-07-16
ME02181B (me)	2015-10-20
KR101421861B1 (ko)	2014-07-22
KR20120128703A (ko)	2012-11-27
LUC00114I1 (el)	2019-04-17
US20110245296A1 (en)	2011-10-06
AR080859A1 (es)	2012-05-16
JP5281718B2 (ja)	2013-09-04
LUC00113I9 (el)	2024-06-07
ES2609636T3 (es)	2017-04-21
PH12012501923A1 (en)	2013-02-04
LTC2924034I2 (lt)	2020-10-12
NL300980I1 (nl)	2019-04-24
CN102971308B (zh)	2015-02-04
LUC00113I2 (el)	2024-05-22
JP5886790B2 (ja)	2016-03-16
CA2794377C (en)	2015-06-16
SG184347A1 (en)	2012-11-29
EP2552902A1 (en)	2013-02-06
DOP2012000256A (es)	2012-12-15
EP2552902B1 (en)	2015-03-11
SI2924034T1 (sl)	2017-05-31
HK1175471A1 (en)	2013-07-05
HUE031785T2 (en)	2017-08-28
HRP20161680T1 (hr)	2017-01-27
PL2924034T3 (pl)	2017-07-31
HUS1900021I1 (hu)	2019-05-28
IL233334A (en)	2015-09-24
CY2019025I2 (el)	2019-11-27
NI201200146A (es)	2013-03-18
LTPA2019507I1 (lt)	2019-04-25
AU2011235568A1 (en)	2012-11-01
NL300980I2 (nl)	2021-06-17
CN102971308A (zh)	2013-03-13
HUS1900022I1 (hu)	2019-05-28
PE20130158A1 (es)	2013-02-28
CY2019026I2 (el)	2020-05-29
EA201290976A1 (ru)	2013-03-29
IL222030A (en)	2014-07-31
EP2552902A4 (en)	2013-09-04
JP2013209405A (ja)	2013-10-10
LTC2552902I2 (lt)	2019-12-10
JP2013510800A (ja)	2013-03-28
LUC00114I2 (el)	2020-07-10

Publication	Publication Date	Title
CY2019025I1 (el)	2019-11-27	Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
DK2421825T3 (da)	2014-02-03	Azetidinyldiamider som monoacylglycerollipase-inhibitorer
SMT201700008B (it)	2017-03-08	Composizione farmaceutica
DK3178818T3 (da)	2019-07-22	Pyrazolylquinoxalinkinasehæmmere
DK3097925T3 (da)	2019-08-05	Farmaceutisk sammensætning
DK3246018T3 (da)	2022-01-17	Farmaceutisk sammensætning
BRPI1004940A2 (pt)	2018-06-19	composição farmacêutica
EP2554796A4 (en)	2014-08-06	TURBINE
EP2613818A4 (en)	2014-08-20	BIODEGRADABLE MULTILAYER CONSTRUCTS
DK4159204T3 (da)	2024-05-21	Hidtil ukendt farmaceutisk sammensætning
BRPI1015939A2 (pt)	2016-09-27	composição farmacêutica
EP2540987A4 (en)	2014-06-04	TURBINE
BR112013013571A2 (pt)	2016-10-11	comprimido para a desintegração oral
EP2552472A4 (en)	2014-03-12	INFLAMMATION INHIBITING FACTORS
EE201300005A (et)	2013-08-15	Ravimkoostis
NL301214I2 (nl)	2023-04-19	Lasmiditan en farmaceutisch aanvaardbare zouten daarvan
HUE043524T2 (hu)	2019-08-28	DGATl inhibitort tartalmazó gyógyászati készítmény
DOP2011000242A (es)	2011-09-15	Macrolido anti-inflamatorio
BR112012003149A2 (pt)	2016-03-01	composição farmacêutica
EP2659889A4 (en)	2014-08-13	FARROWING / PAINFUL COMPOSITION
BR112012029461A2 (pt)	2017-03-01	composição farmacêutica contendo solifenacina
PT2397136T (pt)	2018-07-02	Composição anti-inflamatória
BR112012029887A2 (pt)	2016-08-16	composição farmacêutica
DK2564056T3 (da)	2014-06-30	Turbine
FI20105327L (fi)	2011-10-12	Farmaseuttinen koostumus